NT219
Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
Key Facts
About Purple Biotech
Purple Biotech Ltd. is an Israeli, NASDAQ-listed biotech focused on developing next-generation oncology therapeutics. Its mission is to counteract the primary mechanisms of cancer treatment failure—immune evasion and drug resistance—through targeted agents like the anti-CEACAM1 mAb CM24 and the dual inhibitor NT219. The company's strategy centers on advancing these clinical-stage assets in combination regimens to demonstrate proof-of-concept and unlock significant value. As a micro-cap entity, its near-term trajectory is heavily dependent on clinical readouts from its Phase 2 studies.
View full company profileAbout Purple Biotech
Purple Biotech Ltd. is an Israeli, NASDAQ-listed biotech focused on developing next-generation oncology therapeutics. Its mission is to counteract the primary mechanisms of cancer treatment failure—immune evasion and drug resistance—through targeted agents like the anti-CEACAM1 mAb CM24 and the dual inhibitor NT219. The company's strategy centers on advancing these clinical-stage assets in combination regimens to demonstrate proof-of-concept and unlock significant value. As a micro-cap entity, its near-term trajectory is heavily dependent on clinical readouts from its Phase 2 studies.
View full company profileTherapeutic Areas
Other Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma Drugs
| Drug | Company | Phase |
|---|---|---|
| Pepinemab (VX15/2503) | Vaccinex | Phase 2 |